IMMURON LIMITED (NASDAQ:IMRN) He is One of the best ASX performances in 2025. The company issued its annual report for 2025 on September 25, as it recorded 49 % growth in global revenues for the 2025 fiscal year. He stated that a lot of growth was due to its strong sales of the diarrhea product in the leading traveler, Travelan. North American sales of Traveland increased by 76 % to two million dollars, which is due to the growth of Amazon and Canadian Retail. Australian sales increased by 40 % to $ 5.3 million, with the help of new pharmacy channels.
Nestor Rizhniak/Shutterstock.com
The company’s net loss for the fiscal year reduced by 24 % year on an annual basis to $ 5.25 million. The loss per share was also better than FY2024: A 0.023 dollars for the 2015 fiscal year, compared to $ 0.03. The total margin of this year remained strong at 65.4 %. At the end of the year, Immuron held $ 2.83 million in cash, a decrease of $ 11.66 million in the previous year. The property rights shareholders amounted to $ 8 million, compared to $ 12.7 million in 2024. There was no long debt on the public budget; The total debt remains minimal.
IMMURON LIMITED (NASDAQ: IMRN) is one of the largest biological pharmaceutical companies in Australia. It specializes in the antibodies targeted orally for infectious and infectious diseases. Its pioneering product is Travelan.
While we acknowledge the potential of IMRN as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less negative risks. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.
Read the following: Conservative shares portfolio: 11 best shares for purchase now and 10 best shares for buying now.
Detection: Nothing. This article was originally published in A monkey from the inside.
The post Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales first appeared on Investorempires.com.
